The U.S. Food and Drug Administration (FDA) has declared an end to shortages of the GLP-1 drugs Mounjaro and Zepbound, a move that means online pharmacies will have to stop selling compounded ...
XIFAXAN ® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea ...
In the pivotal Phase 3 VIVID-1 trial, patients treated with Omvoh experienced significant improvement in clinical remission and endoscopic respons ...
The OIG report points to gaps in documentation and decision-making transparency, particularly in the case of Aduhelm, where FDA records indicated only 13 meetings with Biogen, but congressional ...
Alongside over-the-counter NARCAN® Nasal Spray 4 mg, prescription KLOXXADO® (naloxone HCl) Nasal Spray 8 mg will expand Emergent’s ability to ...
EYLEA HD® and EYLEA® remained the U.S. anti-VEGF category leader in 2024; aggregate U.S. net product sales were $6 billion for full-year 2024, up 1% based on preliminary (unaudited) results EYLEA HD ...
NDAQ:AVDL) Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch ...
On January 1, pharmaceutical companies will also lower some of their prices. The list price of Merck & Co.'s heavily discounted diabetes medications Januvia and Janumet will be lowered "to align the ...
Many diabetes patients have experienced lowered drug costs in recent years, thanks to policies that have capped the price of diabetes prescriptions. For patients who have been paying for Ozempic or ...
December 23, 2024, the U.S. Food and Drug Administration approved the first generic referencing Victoza (liraglutide injection) 18 milligram/3 milliliter, a glucagon-like peptide-1 (GLP-1) receptor ...
But a new report from GlobalData indicates Zepbound is poised to overtake other GLP-1 drugs. “Zepbound’s superior efficacy and strategic market expansion suggest that the drug will dominate ...